Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caffeine + dimethylglycine is a patented topical active ingredient complex (Patent EP4221675A1) developed by Dr. Kurt Wolff for the treatment and prevention of hereditary hair loss (androgenetic alopecia). The formulation, marketed under brand names such as Alpecin Caffeine DMG and Plantur DMG Clinical, utilizes a dual-action mechanism to combat hair thinning. Caffeine serves to stimulate hair roots and promote growth, while dimethylglycine sodium salt (DMG-Na) enhances scalp microcirculation by activating endothelial nitric oxide synthase (eNOS) and inducing the production of nitric oxide. This improved blood flow increases the supply of essential nutrients to the hair follicles. Clinical studies published in 2025 have demonstrated that the complex significantly reduces hair loss and improves hair density without notable side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + dimethylglycine.